UK biotech brings in $226M Se­ries C

Apol­lo Ther­a­peu­tics is reel­ing in a $226.5 mil­lion Se­ries C round, the biotech said Wednes­day.

The fi­nanc­ing is two-pronged: It aims to ad­vance Apol­lo’s clin­i­cal pro­grams and back its drug dis­cov­ery ef­forts, and po­ten­tial­ly li­cense or ac­quire clin­i­cal-stage can­di­dates that meet cer­tain cri­te­ria.

“This lat­est fundrais­ing en­ables us to take our most ad­vanced pro­grams to key clin­i­cal val­ue in­flec­tion points,” Apol­lo CEO Richard Ma­son said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER